Stacey Stein, MD
DownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Titles
Assistant Medical Director, Clinical Trials Office
Contact Info
Appointments
Medical Oncology
Primary
Titles
Assistant Medical Director, Clinical Trials Office
Contact Info
Appointments
Medical Oncology
Primary
Titles
Assistant Medical Director, Clinical Trials Office
Contact Info
About
Titles
Associate Professor of Internal Medicine (Medical Oncology)
Assistant Medical Director, Clinical Trials OfficeBiography
I take care of patients with advanced liver cancer and offer chemotherapy. I help educate my patients and their families about their cancer and liver disease. Treatment plans often include a pill form of targeted therapy. There are also immune therapy clinical trials available for patients. I work closely with patients to manage their cancer and liver disease related symptoms.
Appointments
Medical Oncology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- MD
- University of Medicine and Dentistry of New Jersey (2004)
- MMS
- University of Medicine and Dentistry of New Jersey (2000)
- Residency
- Montefiore Medical Center
- Fellowship
- New York University Medical Center
Research
Overview
Stacey’s focus on developing new clinical trials for patients with gastrointestinal cancers
Medical Subject Headings (MeSH)
Clinical Trial; Gastrointestinal Neoplasms
ORCID
0000-0001-8970-9144
Research at a Glance
Yale Co-Authors
Frequent collaborators of Stacey Stein's published research.
Publications Timeline
A big-picture view of Stacey Stein's research output by year.
Jill Lacy, MD
Jeremy Kortmansky, MD
Michael Cecchini, MD
Kimberly L. Johung, MD, PhD
Neal Fischbach, MD
Henry S. Park, MD, MPH
57Publications
403Citations
Publications
2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original Research
2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky J, Canosa S, Sklar J, Swisher E, Radke M, Ivy P, Boerner S, Durecki D, Hsu C, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British Journal Of Cancer 2023, 130: 476-482. PMID: 38135713, PMCID: PMC10844282, DOI: 10.1038/s41416-023-02534-1.Peer-Reviewed Original ResearchAltmetricQuantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2022
Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer
Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPancreatic ductal adenocarcinomaMultiagent chemotherapyPathologic complete responseStereotactic body radiotherapyOverall survivalComplete responseNonmetastatic pancreatic ductal adenocarcinomaNeoadjuvant multiagent chemotherapyMedian overall survivalNational Cancer DatabaseMargin-negative resectionTreatment of choiceDose/fractionSimilar ratesRegional lymphatic diseaseGy/5 fxNeoadjuvant radiotherapyCox analysisSurgical candidacyProspective evaluationPathologic outcomesBody radiotherapyPancreas cancerCancer DatabaseDuctal adenocarcinoma
2021
Emerging Role of Immune Therapy in HCC
Stein S. Emerging Role of Immune Therapy in HCC. Digestive Disease Interventions 2021, 05: 277-282. DOI: 10.1055/s-0041-1722932.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHepatocellular carcinomaImmune therapySingle-agent PD-1 inhibitionVascular endothelial growth factor inhibitionMultiple tyrosine kinase inhibitorAbstract Hepatocellular carcinomaPrevalent cancer diagnosesUnprecedented response ratesPD-1 inhibitionAdvanced hepatocellular carcinomaGrowth factor inhibitionAdvanced diseaseDurable responsesPD-1Combination therapyTreatment optionsFactor inhibitionResponse rateTherapy drugsPatientsKinase inhibitorsTherapyCancer diagnosisModest improvementA phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
He A, Kim A, Toskich B, Mody K, Kim K, Stein S, Goyal L, Abrams T, Brown D, Goff L, Kim R, Parikh N, Sandow T, Johnson D, Iyer R, Petroziello M, Krishnamurthi S, Martin C, Jiang Y, Akhter N. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2021, 39: tps358-tps358. DOI: 10.1200/jco.2021.39.3_suppl.tps358.Peer-Reviewed Original ResearchCitationsConceptsPhase II studyProgression-free survivalHepatocellular carcinomaII studyArm BTARE treatmentBCLC stage B hepatocellular carcinomaAntitumor T-cell activityStage B hepatocellular carcinomaRandomized phase II studyMyeloid-derived suppressor cellsPD-L1 expression levelsIntermediate-stage hepatocellular carcinomaT cell receptor repertoireB hepatocellular carcinomaIntermediate-stage HCCMain secondary objectivesFirst-line treatmentPretreatment liver biopsyRegulatory T cellsT cell infiltrationAdvanced hepatocellular carcinomaDendritic cell maturationT cell activityPatient-reported outcomes
2020
Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis
Miccio J, Mokhtech M, Jabbour S, Anker C, Patel T, Park H, Cecchini M, Salem R, Kuntsman J, Stein S, Kortmansky J, Lacy J, Narang A, Herman J, Haddock M, Hallemeier C, Johung K, Jethwa K. Association of Neoadjuvant Treatment Modality with Negative Margin and Pathologic Downstaging in Patients Undergoing Pancreatic Cancer Resection: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e662. DOI: 10.1016/j.ijrobp.2020.07.1980.Peer-Reviewed Original ResearchThe Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer
Miccio J, Talcott W, Patel T, Park H, Cecchini M, Salem R, Stein S, Kortmansky J, Lacy J, Johung K, Jethwa K. The Utility of Neoadjuvant Radiotherapy after Neoadjuvant Multiagent Chemotherapy in Patients with Localized Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e31-e32. DOI: 10.1016/j.ijrobp.2020.02.538.Peer-Reviewed Original ResearchP-324 Advanced hepatocellular cancer: Current systemic treatment sequencing and outcomes in the United States
Uhlig J, Stein S, Kim H. P-324 Advanced hepatocellular cancer: Current systemic treatment sequencing and outcomes in the United States. Annals Of Oncology 2020, 31: s195. DOI: 10.1016/j.annonc.2020.04.406.Peer-Reviewed Original ResearchCitations
Clinical Trials
Current Trials
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
HIC ID2000033245RoleSub InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
HIC ID2000032928RoleSub InvestigatorPrimary Completion Date03/10/2029Recruiting ParticipantsRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting ParticipantsPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
HIC ID2000027272RoleSub InvestigatorPrimary Completion Date03/01/2024Recruiting Participants
Clinical Care
Overview
Stacey Stein, MD, specializes in medical oncology with a focus on liver and gallbladder cancers, specifically hepatocellular carcinoma, intrahepatic bile duct cancer, and gallbladder neuroendocrine tumors. She is the assistant medical director of the clinical trials office.
Dr. Stein cares for patients with advanced liver disease. She helps to educate her patients and their families about their liver disease. Her interests include chemotherapy, radiotherapy, immunotherapy, biomarkers, precision medicine, gastrointestinal and esophageal cancers, and pancreatic cancer.
Dr. Stein is an associate professor of internal medicine at Yale School of Medicine.
Clinical Specialties
Gastrointestinal Oncology; Medical Oncology
Fact Sheets
Gallbladder Cancer
Learn More on Yale MedicineStomach Cancer
Learn More on Yale MedicinePancreatic Cancer
Learn More on Yale MedicineGastrointestinal Cancers
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- July 24, 2024
Yale Department of Internal Medicine Faculty Promotions and Appointments (July 2024)
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- January 19, 2024
Leading Gastrointestinal and Genitourinary Cancer Conferences to Feature Yale Cancer Center Researchers
- October 10, 2023Source: OncLive
Dr. Stacey Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC
Related Links
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Administrative Support